VENTANA PD-L1 (SP142) Assay (CE IVD)

Predictive IHC assay

PD-L1 SP142 Assay
Do you have any questions?
Contact us
Empowering pathologists to answer PD-L1 questions
VENTANA PD-L1 (SP142) Assay* gives you the confidence to:

 

  • Identify triple–negative breast cancer (TNBC) patients eligible for treatment with TECENTRIQ® (atezolizumab)
  • Identify urothelial carcinoma (UC) patients eligible for treatment with TECENTRIQ® (atezolizumab)
  • Identify non-small cell lung cancer (NSCLC) patients eligible for treatment with TECENTRIQ® (atezolizumab)

* VENTANA PD-L1 (SP142) Assay may not be available for some indications and/or cutoffs in all geographies. In Switzerland TECENTRIQ is approved for non-small cell lung cancer only.

Companion diagnostic indications
Triple-negative breast cancer, urothelial carcinoma and non-small cell lung cancer

 

Using the right test to determine PD-L1 status for immunotherapy options is important. VENTANA PD-L1 (SP142) Assay* is the first and only CE-IVD marked test for TECENTRIQ in triple–negative breast cancer (TNBC) and urothelial carcinoma (UC) and non-small cell lung cancer (NSCLC) patients. This novel assay is also the first to evaluate patient PD-L1 expression using immune cell staining and scoring within the tumor microenvironment, providing you with information that can guide immunotherapy decisions.

 

VENTANA PD-L1 (SP142) Assay:

 

  • Designed to enhance visual contrast of immune cell staining  within the tumor microenvironment
  • First PD-L1 assay CE-IVD marked with an immune cell scoring algorithm
  • First and only PD-L1 assay clinically proven to identify patients eligible for and most likely to benefit from TECENTRIQ
Complementary diagnostic indications
Non-small cell lung cancer (NSCLC)

 

Using the right test to determine PD-L1 status for immunotherapy options is important, and the VENTANA PD-L1 (SP142) Assay is the only CE-IVD marked test for TECENTRIQ. This innovative assay is the first to evaluate patient PD-L1 expression using both tumor cell (TC) and tumor-infiltrating immune cell (IC) staining. Determining a patient’s PD-L1 expression level can give insight to the overall survival that may be achieved from TECENTRIQ.*

 

VENTANA PD-L1 (SP142) Assay:

 

  • Only CE-IVD marked test to assess NSCLC patient treatment benefit from TECENTRIQ
  • Informative for the clinician of a patient’s potential overall survival
  • Novel scoring algorithm using PD-L1 staining in both TC and IC
  • Designed to enhance visual contrast of immune cell staining within the tumor microenvironment

*All randomized patients in a NSCLC phase III study observed benefit from TECENTRIQ regardless of PD-L1 status.

Product specifications

VENTANA PD-L1 (SP142) Assay is intended for the immunohistochemical assessment of the programmed death-ligand 1 (PD-L1) protein in tumor cells and tumor-infiltrating immune cells in formalin-fixed, paraffin-embedded (FFPE) tissues indicated below stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a BenchMark IHC/ISH instrument.

Determination of PD-L1 status is indication-specific and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.

Table 1. Companion diagnostic indications for the VENTANA PD-L1 (SP142) Assay.

Se hela tabellen

Table 1. Companion diagnostic indications for the VENTANA PD-L1 (SP142) Assay.

Indication for use Therapy
Cutoff
Urothelial Carcinoma
atezolizumab ≥ 5% IC
Triple–Negative Breast Carcinoma (TNBC)
≥ 1% IC
Non-Small Cell Lung Cancer (NSCLC) ≥ 50% TC or ≥ 10% IC

VENTANA PD-L1 (SP142) Assay complementary diagnostic indication

Se hela tabellen

VENTANA PD-L1 (SP142) Assay complementary diagnostic indication

VENTANA PD-L1 (SP142) Assay may be associated with enhanced patient benefit with the therapies listed in this table for the corresponding indication and cutoffs in accordance with the approved therapeutic product labeling.

Indication for use Therapy
Cutoff
Non-small Cell Lung Cancer (NSCLC) TECENTRIQ* ≥ 50% TC or ≥ 10% IC
Non-small Cell Lung Cancer (NSCLC) TECENTRIQ* ≥ 1% TC or ≥ 1% IC

References

 

* The international non-proprietary name (INN) for TECENTRIQ is atezolizumab.

Depending on therapeutic setting, PD-L1 expression in ≥ 50% TC or ≥ 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from TECENTRIQ (atezolizumab). Refer to the approved therapeutic product labeling for further information.

Test results of this product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This product is intended for in vitro diagnostic (IVD) use.

Depending on therapeutic setting, PD-L1 expression in ≥ 50% TC or ≥ 10% IC determined by VENTANA PD-L1 (SP142) Assay in non-small cell lung cancer (NSCLC) patients may be associated with enhanced overall survival from atezolizumab. Refer to the approved therapeutic product labeling for further information.

Test results of this product should be interpreted by a qualified pathologist in conjunction with histological examination, relevant clinical information, and proper controls.

This product is intended for in vitro diagnostic (IVD) use.

 

Take an in-depth look at the VENTANA PD-L1 (SP142) Assay (CE IVD)

Search our product catalogs and documentation library in eLabDoc.

Roche lung cancer IHC panel in eLabDoc